Your browser doesn't support javascript.
loading
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele.
Goralski, Jennifer L; Hoppe, Jordana E; Mall, Marcus A; McColley, Susanna A; McKone, Edward; Ramsey, Bonnie; Rayment, Jonathan H; Robinson, Phil; Stehling, Florian; Taylor-Cousar, Jennifer L; Tullis, Elizabeth; Ahluwalia, Neil; Chin, Anna; Chu, Chenghao; Lu, Mengdi; Niu, Tao; Weinstock, Tanya; Ratjen, Felix; Rosenfeld, Margaret.
Afiliación
  • Goralski JL; University of North Carolina School of Medicine, Chapel Hill, North Carolina.
  • Hoppe JE; University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado.
  • Mall MA; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • McColley SA; Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • McKone E; German Center for Lung Research, Associated Partner, Berlin, Germany.
  • Ramsey B; Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Rayment JH; St. Vincent's Hospital, Dublin, Ireland.
  • Robinson P; Seattle Children's Research Institute, Seattle, Washington.
  • Stehling F; Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington.
  • Taylor-Cousar JL; University of British Columbia and British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
  • Tullis E; The Royal Children's Hospital, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • Ahluwalia N; Department of Pediatrics, University of Melbourne, Melbourne, Victoria, Australia.
  • Chin A; Children's Hospital, University of Duisburg-Essen, Essen, Germany.
  • Chu C; National Jewish Health, Denver, Colorado.
  • Lu M; St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Niu T; Vertex Pharmaceuticals Inc., Boston, Massachusetts; and.
  • Weinstock T; Vertex Pharmaceuticals Inc., Boston, Massachusetts; and.
  • Ratjen F; Vertex Pharmaceuticals Inc., Boston, Massachusetts; and.
  • Rosenfeld M; Vertex Pharmaceuticals Inc., Boston, Massachusetts; and.
Am J Respir Crit Care Med ; 208(1): 59-67, 2023 07 01.
Article en En | MEDLINE | ID: mdl-36921081
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrosis Quística Tipo de estudio: Clinical_trials Límite: Aged / Child / Humans Idioma: En Revista: Am J Respir Crit Care Med Asunto de la revista: TERAPIA INTENSIVA Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrosis Quística Tipo de estudio: Clinical_trials Límite: Aged / Child / Humans Idioma: En Revista: Am J Respir Crit Care Med Asunto de la revista: TERAPIA INTENSIVA Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos